See more : Great Harvest Maeta Holdings Limited (3683.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Agree Realty Corporation (ADC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Agree Realty Corporation, a leading company in the REIT – Retail industry within the Real Estate sector.
You may be interested
- Mason Graphite Inc. (LLG.V) Income Statement Analysis – Financial Results
- Sierra Income Corporation (SIRR) Income Statement Analysis – Financial Results
- Magellan Health, Inc. (MGLN) Income Statement Analysis – Financial Results
- Lion One Metals Limited (LLO.AX) Income Statement Analysis – Financial Results
- LuxUrban Hotels Inc. (CHG) Income Statement Analysis – Financial Results
Agree Realty Corporation (ADC)
About Agree Realty Corporation
Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 537.50M | 463.15M | 363.61M | 248.57M | 187.48M | 148.20M | 116.56M | 91.53M | 69.97M | 53.56M | 43.52M | 35.79M | 36.32M | 36.11M | 37.26M | 35.65M | 34.47M | 32.91M | 31.58M | 29.93M | 27.47M | 25.82M | 24.68M | 23.73M | 21.93M | 19.67M | 18.23M | 16.29M | 13.80M | 9.50M |
| Cost of Revenue | 239.67M | 85.62M | 65.34M | 31.75M | 23.51M | 17.01M | 12.47M | 8.60M | 6.38M | 4.92M | 3.66M | 3.58M | 4.91M | 3.85M | 2.43M | 64.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 297.83M | 377.53M | 298.26M | 216.82M | 163.97M | 131.18M | 104.09M | 82.93M | 63.59M | 48.64M | 39.86M | 32.21M | 31.41M | 32.26M | 34.83M | 35.59M | 34.47M | 32.91M | 31.58M | 29.93M | 27.47M | 25.82M | 24.68M | 23.73M | 21.93M | 19.67M | 18.23M | 16.29M | 13.80M | 9.50M |
| Gross Profit Ratio | 55.41% | 81.51% | 82.03% | 87.23% | 87.46% | 88.52% | 89.30% | 90.61% | 90.88% | 90.82% | 91.60% | 90.00% | 86.48% | 89.34% | 93.49% | 99.82% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.37 | 0.37 | 0.37 | 0.43 | 0.43 | 0.50 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 34.79M | 30.12M | 25.46M | 20.79M | 15.57M | 12.17M | 9.95M | 8.02M | 6.99M | 6.63M | 5.95M | 5.68M | 5.66M | 5.00M | 4.56M | 6.94M | 4.46M | 4.02M | 4.19M | 2.85M | 2.28M | 2.01M | 1.81M | 1.56M | 1.42M | 1.17M | 1.11M | 1.10M | 1.00M | 700.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 88.00 | -384.00 | 859.00K | -2.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.79M | 30.12M | 25.46M | 20.79M | 15.57M | 12.17M | 9.95M | 8.02M | 6.99M | 6.63M | 5.95M | 5.68M | 5.66M | 5.00M | 5.42M | 4.36M | 4.46M | 4.02M | 4.19M | 2.85M | 2.28M | 2.01M | 1.81M | 1.56M | 1.42M | 1.17M | 1.11M | 1.10M | 1.00M | 700.00K |
| Other Expenses | 0.00 | 133.57M | 95.73M | 66.76M | 45.70M | 4.00K | 347.00K | 23.41M | 16.49M | 11.10M | 8.49M | 6.47M | 6.50M | 5.69M | 7.65M | 7.25M | 9.33M | 9.07M | 9.19M | 8.96M | 7.58M | 8.19M | 7.99M | 7.46M | 6.95M | 6.12M | 5.57M | 5.11M | -5.60M | -4.20M |
| Operating Expenses | 216.39M | 163.69M | 121.19M | 87.55M | 61.27M | 55.86M | 41.70M | 31.42M | 23.47M | 17.73M | 14.44M | 12.15M | 12.16M | 10.69M | 14.63M | 19.37M | 13.79M | 13.09M | 13.38M | 11.81M | 9.86M | 10.20M | 9.79M | 9.02M | 8.37M | 7.29M | 6.67M | 6.21M | -4.60M | -3.50M |
| Cost & Expenses | 283.11M | 249.31M | 186.53M | 119.30M | 84.78M | 72.87M | 54.17M | 40.02M | 29.85M | 22.65M | 18.10M | 15.73M | 17.07M | 14.54M | 14.63M | 19.37M | 13.79M | 13.09M | 13.38M | 11.81M | 9.86M | 10.20M | 9.79M | 9.02M | 8.37M | 7.29M | 6.67M | 6.21M | -4.60M | -3.50M |
| Interest Income | 0.00 | 63.44M | 50.38M | 40.10M | 33.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 770.18K | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 81.12M | 63.44M | 66.35M | 44.66M | 32.98M | 0.00 | 0.00 | 0.00 | 0.00 | 8.59M | 6.48M | 5.13M | 4.73M | 4.71M | 4.64M | 5.18M | 4.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 209.37M | 212.74M | 162.25M | 123.44M | 86.39M | 64.12M | 54.17M | 40.02M | 16.49M | 11.10M | 8.49M | 6.47M | 6.50M | 5.69M | 5.71M | 5.39M | 5.20M | 4.99M | 207.04K | 4.62M | 4.82M | 4.22M | 4.22M | 4.06M | 3.80M | 3.51M | 3.19M | 3.03M | 2.60M | 2.00M |
| EBITDA | 463.95M | 386.24M | 295.67M | 192.16M | 161.45M | 118.63M | 94.14M | 74.92M | 56.60M | 42.01M | 34.05M | 26.19M | 19.73M | 14.85M | 28.34M | 21.67M | 25.88M | 24.81M | 23.15M | 17.57M | 19.81M | 19.17M | 17.97M | 18.24M | 17.29M | 15.89M | 14.75M | 13.11M | 21.00M | 15.00M |
| EBITDA Ratio | 86.32% | 74.08% | 75.47% | 77.31% | 72.92% | 74.33% | 68.59% | 71.33% | 63.81% | 78.44% | 77.92% | 74.12% | 74.44% | 96.81% | 76.05% | 60.77% | 72.05% | 75.39% | 72.28% | 75.26% | 87.07% | 74.23% | 72.83% | 76.87% | 78.84% | 80.75% | 80.91% | 76.46% | 152.17% | 157.89% |
| Operating Income | 254.39M | 218.09M | 190.27M | 125.13M | 101.09M | 73.00M | 62.39M | 51.51M | 40.11M | 27.89M | 25.42M | 20.06M | 15.60M | 13.87M | 22.63M | 16.28M | 20.68M | 19.82M | 18.21M | 18.12M | 16.65M | 15.62M | 15.10M | 14.71M | 13.56M | 12.38M | 11.56M | 10.08M | 18.40M | 13.00M |
| Operating Income Ratio | 47.33% | 47.09% | 52.33% | 50.34% | 53.92% | 49.26% | 53.53% | 56.28% | 57.33% | 52.07% | 58.41% | 56.05% | 42.94% | 38.42% | 60.73% | 45.67% | 59.99% | 60.23% | 57.65% | 60.54% | 60.61% | 60.50% | 61.20% | 61.98% | 61.83% | 62.93% | 63.40% | 61.88% | 133.33% | 136.84% |
| Total Other Income/Expenses | -80.93M | -62.19M | -64.99M | -40.07M | -33.09M | -13.69M | -3.37M | -5.71M | -351.00K | -9.12M | -6.47M | -5.13M | 506.14K | -4.71M | 0.00 | -14.46M | 1.04M | -4.62M | 12.79K | -4.29M | 176.08K | 673.58K | 1.13M | 522.34K | 68.61K | 0.00 | 0.00 | 653.07K | 0.00 | 0.00 |
| Income Before Tax | 173.46M | 155.90M | 125.28M | 93.06M | 81.30M | 59.31M | 58.79M | 45.80M | 39.76M | 18.78M | 18.95M | 14.92M | 9.55M | 15.07M | 15.48M | 15.48M | 21.72M | 0.00 | 18.22M | 18.34M | 15.17M | 16.30M | 16.23M | 15.23M | 13.63M | 0.00 | 0.00 | 10.73M | 0.00 | 0.00 |
| Income Before Tax Ratio | 32.27% | 33.66% | 34.45% | 37.44% | 43.37% | 40.02% | 50.44% | 50.04% | 56.83% | 35.05% | 43.54% | 41.70% | 26.30% | 41.72% | 41.55% | 43.42% | 63.02% | 0.00% | 57.69% | 61.27% | 55.21% | 63.11% | 65.78% | 64.18% | 62.14% | 0.00% | 0.00% | 65.89% | 0.00% | 0.00% |
| Income Tax Expense | 2.91M | 2.86M | 2.40M | 1.09M | 538.00K | 516.00K | 4.62M | 6.39M | 1.10M | 8.87M | -728.73K | -3.13M | 9.70M | 6.51M | -9.83M | -13.20M | 5.20M | 5.84M | 6.58M | 5.00M | 7.14M | 6.85M | 6.82M | 7.61M | 6.75M | 6.29M | 6.34M | 6.35M | 15.20M | 12.70M |
| Net Income | 169.96M | 152.44M | 122.27M | 91.38M | 80.08M | 58.17M | 58.11M | 45.12M | 39.02M | 18.49M | 19.68M | 18.05M | 9.55M | 15.07M | 17.99M | 15.02M | 15.48M | 13.97M | 16.05M | 13.12M | 10.47M | 8.77M | 8.07M | 7.10M | 6.81M | 6.09M | 5.22M | 3.73M | 3.20M | 300.00K |
| Net Income Ratio | 31.62% | 32.91% | 33.63% | 36.76% | 42.71% | 39.25% | 49.86% | 49.29% | 55.77% | 34.52% | 45.21% | 50.43% | 26.30% | 41.72% | 48.29% | 42.12% | 44.92% | 42.46% | 50.82% | 43.85% | 38.12% | 33.97% | 32.68% | 29.91% | 31.04% | 30.94% | 28.63% | 22.92% | 23.19% | 3.16% |
| EPS | 1.70 | 1.84 | 1.79 | 1.76 | 1.96 | 1.81 | 2.09 | 1.97 | 2.17 | 1.24 | 1.51 | 1.63 | 0.99 | 1.54 | 2.20 | 1.91 | 2.02 | 1.84 | 2.15 | 2.03 | 1.63 | 1.99 | 1.81 | 1.61 | 1.56 | 1.40 | 1.41 | 1.41 | 1.23 | 0.08 |
| EPS Diluted | 1.70 | 1.83 | 1.78 | 1.74 | 1.93 | 1.80 | 2.08 | 1.97 | 2.16 | 1.24 | 1.50 | 1.62 | 0.99 | 1.54 | 2.14 | 1.91 | 2.01 | 1.83 | 2.14 | 2.03 | 1.63 | 1.97 | 1.81 | 1.61 | 1.56 | 1.40 | 1.41 | 1.41 | 1.23 | 0.08 |
| Weighted Avg Shares Out | 95.19M | 78.66M | 66.80M | 51.84M | 40.58M | 32.07M | 27.63M | 22.87M | 18.00M | 14.88M | 13.07M | 11.07M | 9.64M | 9.76M | 7.90M | 7.68M | 7.65M | 7.59M | 7.46M | 6.46M | 4.88M | 4.45M | 4.42M | 4.41M | 4.36M | 4.36M | 3.69M | 2.65M | 2.60M | 3.21M |
| Weighted Avg Shares Out (Dil) | 95.44M | 79.16M | 67.14M | 52.40M | 41.22M | 32.40M | 27.70M | 22.96M | 18.07M | 14.97M | 13.16M | 11.14M | 9.68M | 9.76M | 8.42M | 8.38M | 7.72M | 7.64M | 7.50M | 6.46M | 5.26M | 4.45M | 4.42M | 4.41M | 4.36M | 4.36M | 3.69M | 2.65M | 2.60M | 3.21M |
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will hold an investor webcast to discuss data from a Phase 1 clinical trial of ZL-1310, the Company's investigational DLL3-targeted antibody-drug conjugate (ADC), in patients...
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the dose escalation part of...
U.S. REITs Log Dip In Short Interest In September
Average REIT short interest fell 8 basis points in September to 3.7% of shares outstanding, per S&P Global Market Intelligence data. The hotel sector followed with a 60-basis point drop, while the office sector remained the most-shorted at 5.3% of...
Resolving Dilemma Between Realty Income And Agree Realty
Realty Income and Agree Realty are structurally similar REITs with a strong focus on the net lease retail segment and very defensive fundamentals. Yet, as a durable income investor, who seeks to maximize yield, while keeping the dividend cut risk...
3 Of The Biggest Lessons Of My 30+ Year Investing Career
My career in real estate development taught me the importance of analyzing financial statements and identifying durable competitive advantages, much like stock investing. Transparency is crucial; my bad experience with a dishonest business partner led me to prefer REITs over...
8 Dividend Stocks On My Buy List As Inflation Keeps Dropping
Disinflationary trends persist, with CPI showing a steady decline, despite media drama over slightly higher-than-expected figures; energy stocks remain attractive for long-term investors. Realty Income should consider breaking into smaller REITs for better growth. Protectionist tariffs hurt US manufacturing, and...
2 Small Cap, Growing BDCs That Could Be Great Income Additions To Your Portfolio
Income investors should consider Crescent Capital BDC and Fidus Investment for their portfolios, as both trade below Net Asset Values and offer growth potential. CCAP, despite a short track record, shows strong investment activity, solid balance sheet, and consistent dividend...
Agree Realty Declares Increased Monthly Common Dividend
Increase Results in 2.4% Year-Over-Year Growth and Annualized Dividend of $3.036 Per Share ROYAL OAK, Mich. , Oct. 10, 2024 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that its Board of Directors has authorized, and the...
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; “Zai Lab”) today announced that data from a Phase 1 study of ZL-1310, the Company's investigational antibody-drug conjugate (ADC), will be presented during a plenary session at the EORTC-NCI-AACR...
Source: https://incomestatements.info
Category: Stock Reports